Biguanide
Star1
This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Identification
- Generic Name
- Biguanide
- DrugBank Accession Number
- DB13100
- Background
Biguanide has been investigated for the treatment of Diabetes Mellitus.
- Type
- Small Molecule
- Groups
- Approved, Investigational
- Structure
- Weight
- Average: 101.113
Monoisotopic: 101.070145245 - Chemical Formula
- C2H7N5
- Synonyms
- Not Available
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Contraindications & Blackbox Warnings
- Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API
- Pharmacodynamics
Not Available
- Mechanism of action
- Not Available
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
- Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.
- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.Not Available
- Food Interactions
- Not Available
Products
- Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.
Categories
- Drug Categories
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of organic compounds known as biguanides. These are organic compounds containing two N-linked guanidines.
- Kingdom
- Organic compounds
- Super Class
- Organic nitrogen compounds
- Class
- Organonitrogen compounds
- Sub Class
- Guanidines
- Direct Parent
- Biguanides
- Alternative Parents
- Carboximidamides / Organopnictogen compounds / Imines / Hydrocarbon derivatives
- Substituents
- Aliphatic acyclic compound / Biguanide / Carboximidamide / Hydrocarbon derivative / Imine / Organopnictogen compound
- Molecular Framework
- Aliphatic acyclic compounds
- External Descriptors
- guanidines (CHEBI:3095)
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- FB4Q52I9K2
- CAS number
- 56-03-1
- InChI Key
- XNCOSPRUTUOJCJ-UHFFFAOYSA-N
- InChI
- InChI=1S/C2H7N5/c3-1(4)7-2(5)6/h(H7,3,4,5,6,7)
- IUPAC Name
- carbamimidamidomethanimidamide
- SMILES
- NC(=N)NC(N)=N
References
- General References
- Not Available
- External Links
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 4 Completed Treatment Atherosclerosis / Diabetes / Restenosis 1 3 Completed Treatment Diabetes Mellitus 1 3 Completed Treatment Disorder of Glucose Regulation / Polycystic Ovarian Syndrome (PCOS) 1 3 Completed Treatment Type 2 Diabetes Mellitus 3 2 Recruiting Treatment Impaired Glucose Tolerance / Insulin Sensitivity / Metabolism Disorder, Glucose 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
Form Route Strength Capsule 250 MG - Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 1.81 mg/mL ALOGPS logP -2.1 ALOGPS logP -1.5 Chemaxon logS -1.8 ALOGPS pKa (Strongest Acidic) 19.2 Chemaxon pKa (Strongest Basic) 12.06 Chemaxon Physiological Charge 2 Chemaxon Hydrogen Acceptor Count 5 Chemaxon Hydrogen Donor Count 5 Chemaxon Polar Surface Area 111.77 Å2 Chemaxon Rotatable Bond Count 0 Chemaxon Refractivity 46.57 m3·mol-1 Chemaxon Polarizability 9.4 Å3 Chemaxon Number of Rings 0 Chemaxon Bioavailability 1 Chemaxon Rule of Five Yes Chemaxon Ghose Filter No Chemaxon Veber's Rule No Chemaxon MDDR-like Rule No Chemaxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
- Chromatographic Properties
Collision Cross Sections (CCS)
Adduct CCS Value (Å2) Source type Source [M-H]- 113.446138 predictedDarkChem Lite v0.1.0 [M-H]- 124.23683 predictedDeepCCS 1.0 (2019) [M+H]+ 114.246938 predictedDarkChem Lite v0.1.0 [M+H]+ 126.23929 predictedDeepCCS 1.0 (2019) [M+Na]+ 134.51794 predictedDeepCCS 1.0 (2019)
Drug created at October 21, 2016 03:05 / Updated at June 12, 2020 16:53